Zacks Research Has Bearish Estimate for BHC Q1 Earnings

Bausch Health Cos Inc. (NYSE:BHC) – Investment analysts at Zacks Research decreased their Q1 2026 EPS estimates for Bausch Health Cos in a report issued on Wednesday, March 11th. Zacks Research analyst Team now anticipates that the company will post earnings of $0.81 per share for the quarter, down from their previous forecast of $0.82. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Cos’ Q2 2026 earnings at $0.94 EPS, Q3 2026 earnings at $1.06 EPS, Q4 2026 earnings at $1.10 EPS, FY2026 earnings at $3.92 EPS, Q1 2027 earnings at $0.82 EPS, Q3 2027 earnings at $1.12 EPS, Q4 2027 earnings at $0.97 EPS and FY2027 earnings at $3.79 EPS.

Bausch Health Cos (NYSE:BHC) last issued its quarterly earnings data on Wednesday, February 18th. The company reported $1.08 EPS for the quarter, missing the consensus estimate of $1.21 by ($0.13). Bausch Health Cos had a return on equity of 875.00% and a net margin of 1.53%.The company had revenue of $2.78 billion during the quarter, compared to the consensus estimate of $2.71 billion.

Several other analysts have also commented on BHC. Weiss Ratings lowered shares of Bausch Health Cos from a “hold (c)” rating to a “sell (d+)” rating in a report on Thursday, February 19th. Wall Street Zen lowered Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 15th. Barclays lowered their target price on Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 25th. Truist Financial lifted their price target on Bausch Health Cos from $7.00 to $8.00 and gave the company a “hold” rating in a research report on Wednesday, January 7th. Finally, Raymond James Financial reiterated a “market perform” rating on shares of Bausch Health Cos in a report on Monday, January 26th. Four research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $8.33.

Bausch Health Cos Price Performance

Shares of NYSE BHC opened at $5.06 on Thursday. Bausch Health Cos has a 1 year low of $4.25 and a 1 year high of $8.69. The stock has a market capitalization of $1.88 billion, a P/E ratio of 12.04 and a beta of 0.37. The company’s 50-day moving average is $6.24 and its 200 day moving average is $6.55. The company has a debt-to-equity ratio of 54.68, a current ratio of 1.47 and a quick ratio of 1.08.

Hedge Funds Weigh In On Bausch Health Cos

Large investors have recently made changes to their positions in the business. Paulson & CO. Inc. grew its holdings in shares of Bausch Health Cos by 24.0% during the second quarter. Paulson & CO. Inc. now owns 32,791,702 shares of the company’s stock valued at $218,393,000 after buying an additional 6,352,667 shares during the last quarter. Vanguard Group Inc. raised its holdings in Bausch Health Cos by 4.0% in the 3rd quarter. Vanguard Group Inc. now owns 12,241,072 shares of the company’s stock worth $78,808,000 after acquiring an additional 470,968 shares during the last quarter. Acadian Asset Management LLC lifted its position in Bausch Health Cos by 16.2% in the 2nd quarter. Acadian Asset Management LLC now owns 782,386 shares of the company’s stock valued at $5,193,000 after acquiring an additional 109,070 shares in the last quarter. Goldentree Asset Management LP boosted its stake in Bausch Health Cos by 13.2% during the 2nd quarter. Goldentree Asset Management LP now owns 34,254,889 shares of the company’s stock valued at $227,848,000 after purchasing an additional 4,004,889 shares during the last quarter. Finally, Maple Rock Capital Partners Inc. boosted its stake in Bausch Health Cos by 14.9% during the 2nd quarter. Maple Rock Capital Partners Inc. now owns 7,808,487 shares of the company’s stock valued at $52,005,000 after purchasing an additional 1,010,987 shares during the last quarter. 78.65% of the stock is currently owned by hedge funds and other institutional investors.

Bausch Health Cos News Roundup

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Zacks raised its FY2026 outlook slightly (to $3.92 from $3.91) and increased several quarter forecasts (Q4 2026 to $1.10, Q2 2026 to $0.94, Q1 2027 to $0.82, and Q3 2027 to $1.12), which suggests stronger near-term earnings visibility. MarketBeat: BHC analyst note
• Neutral Sentiment: Zacks’ revisions are small and the firm’s FY2026/FY2027 targets (FY2026 $3.92; FY2027 $3.79) remain below the broader consensus ($4.41), so impact may be muted unless other brokers follow suit. MarketBeat: BHC analyst note
• Negative Sentiment: Zacks cut several forward estimates (Q1 2026 to $0.81, Q3 2026 to $1.06, Q4 2027 to $0.97 and trimmed FY2027 to $3.79 from $3.85), signaling slightly weaker longer‑range expectations that can weigh on sentiment and share price. MarketBeat: BHC analyst note

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.